Price Chart

Profile

Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.
URL https://www.neurocrine.com
Investor Relations URL https://neurocrine.gcs-web.com/
HQ State/Province California
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Equity Style Mid Cap/Growth
Next Earnings Release May. 03, 2024 (est.)
Last Earnings Release Feb. 07, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date Dec. 29, 1995

Profile

Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.
URL https://www.neurocrine.com
Investor Relations URL https://neurocrine.gcs-web.com/
HQ State/Province California
Sector Healthcare
Industry Drug Manufacturers - Specialty & Generic
Equity Style Mid Cap/Growth
Next Earnings Release May. 03, 2024 (est.)
Last Earnings Release Feb. 07, 2024
Next Ex-Dividend Date N/A
Last Ex-Dividend Date Dec. 29, 1995